Apixaban Dose Reduction in Patients With Elevated Drug Levels
Launched by HAMILTON HEALTH SCIENCES CORPORATION · Jun 21, 2016
Trial Information
Current as of July 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with non-valvular atrial fibrillation (permanent, paroxysmal, or persistent) receiving apixaban with any of the following characteristics: age\>85; creatinine clearance \<40mL/min; or body weight \<50kg.
- Exclusion Criteria:
- • Inability to visit Hamilton General Hospital;
- • Inability or unwillingness to provide written informed consent.
- • Stroke or thromboembolic event in the past 6 months.
About Hamilton Health Sciences Corporation
Hamilton Health Sciences Corporation is a leading healthcare provider in Canada, renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on translating scientific discoveries into effective treatments, the organization operates a network of hospitals and specialized centers that facilitate cutting-edge research across various medical disciplines. Hamilton Health Sciences is dedicated to fostering collaboration among researchers, healthcare professionals, and industry partners, ensuring that clinical trials are conducted with the highest ethical standards and rigor. Through its robust research infrastructure, the corporation aims to enhance health outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Vinai C. Bhagirath, MD MSc.
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials